SSR 69071 Chemical Properties

storage temp. 

Store at +4°C

solubility 

Soluble in DMSO

form 

solid

color 

Off-white

SSR 69071 Usage And Synthesis

Description

SSR 69071 is a potent inhibitor of neutrophil elastase (K_i = 0.0168 nM for the human enzyme). It is selective for human neutrophil elastase over rat, mouse, and rabbit elastases (K_is = 3, 1.8, 58 nM, respectively). It inhibits human neutrophil elastase ex vivo in mouse bronchoalveolar lavage (BAL) fluid (ED₅₀ = 10.5 mg/kg, p.o.). In vivo, SSR 69071 (2.8 mg/kg, p.o.) reduces acute lung hemorrhage induced by human neutrophil elastase in mice. It reduces carrageenan- and human neutrophil elastase-induced paw edema in rats (ED₃₀s = 2.2 and 2.7 mg/kg, respectively). SSR 69071 also reduces cardiac infarct size when administered prior to ischemia or reperfusion in a rabbit model of ischemia-reperfusion injury.

Uses

SSR 69071 is a novel and orally active elastase inhibitor.

Definition

ChEBI: 6-methoxy-1,1-dioxo-2-[[4-oxo-9-[2-(1-piperidinyl)ethoxy]-2-pyrido[1,2-a]pyrimidinyl]oxymethyl]-4-propan-2-yl-1,2-benzothiazol-3-one is a pyridopyrimidine.

Biological Activity

Orally active, high affinity and potent inhibitor of human leukocyte elastase (HLE) (IC 50 = 3.9 nM). Displays species-selectivity (K i values are 0.017, 1.70, 3.01, 58 and > 100 nM? for human, mouse, rat, rabbit and porcine elastase respectively). In vivo, inhibits HLE-induced lung hemorrhage in mice (ID 50 = 2.8 mg/kg) and reduces infarct size in an acute model of coronary ischemia-reperfusion injury.

storage

Store at +4°C

References

[1] ZOLTAN KAPUI. Biochemical and pharmacological characterization of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor.[J]. Journal of Pharmacology and Experimental Therapeutics, 2003, 305 2: 451-459. DOI: 10.1124/jpet.102.044263
[2] JEAN-PIERRE BIDOUARD . SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia–reperfusion injury[J]. European journal of pharmacology, 2003, 461 1: Pages 49-52. DOI: 10.1016/s0014-2999(03)01298-6

SSR 69071(344930-95-6)Related Product Information

• SSR 69071
• N-HYDROXYMETHYLSACCHARIN
• 1,2-BENZISOTHIAZOL-3(2H)-ONE, 6-METHOXY, 1,1-DIOXIDE